Projects per year
Personal profile
Research interests
Chronic viral hepatitis
Evaluation of novel therapeutic agents for chronic viral hepatitis: Clinical trials are examining, for example, several new interferon-free therapies involving combinations of direct acting antiviral agents as well as novel immunological therapies involving HCV-peptide-treated leucocytes. The role of Vitamin D and a range of host genetic markers (such as IL-28B, ITPA) on both treatment outcomes and the severity of liver histology in CHC, and the immunological mechanisms of HCV clearance and effect of HCV on cognitive function in chronically infected patients are also being investigated. Early phase 1 clinical studies are underway to examine novel immune-mediated and anti-viral treatment options for patients with chronic hepatitis B.
Primary liver cancer
Therapeutic approaches to primary liver cancer: We are evaluating novel first- and second-line therapies options in patients with advanced disease as well as comparing the outcomes of local ablation or hepatic resection in those with early stage disease. In addition, large retrospective studies are being performed to determine whether the aetiology of liver cancer (ie. viral versus non-viral) impacts on patient survival.
Fibroscan evaluation
Evaluation of the Fibroscan: Since acquiring the first Fibroscan machine in Australia 4 years ago to assess liver disease via non-invasive measurement of liver stiffness (LSM), several clinical studies have been performed evaluating LSM as a screening and diagnostic tool for liver disease. Patient populations studied include cystic fibrosis, haemophilia, hepatitis C, NAFLD and diabetes. The utility of LSM is also being evaluated as a predictor of outcome of antiviral therapy in patients with hepatitis C, of complications of liver disease in patients with cirrhosis.
Non-alcoholic fatty liver disease
Management of patients with non-alcoholic fatty liver disease (NAFLD): A pilot study is underway examining the therapeutic effect of high dose Vitamin D in NAFLD. Pilot studies are planned in 2013 to evaluate novel therapeutic agents and the institution of a formal lifestyle programme (in conjunction with members of the Dietetics Department).
Evaluating hepatic encephalopathy
Evaluation of the prevalence, clinical significance and management of minimal hepatic encephalopathy in patients with chronic liver disease.
Keywords
- hepatology
- Chronic viral hepatitis
- primary liver cancer
- fibroscan evaluation
- non-alcoholic fatty liver disease
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2019 2023
- 3 Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination with Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma who are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2).
17/05/19 → 31/05/23
Project: Research
An Open-Label Study to Assess The Efficacy and Safety of LM011 In Subjects Diagnosed With Non-Alcoholic Steatohepatitis (NASH).
16/04/19 → 31/12/19
Project: Research
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1).
Roberts, S. & Lewis, P.
24/01/19 → 30/04/23
Project: Research
Research Output 1997 2018
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial
Wade, A. J., Doyle, J. S., Gane, E., Stedman, C., Draper, B., Iser, D., Roberts, S. K., Kemp, W., Petrie, D., Scott, N., Higgs, P., Agius, P. A., Roney, J., Stothers, L., Thompson, A. J. & Hellard, M. E., 16 Jul 2018, In : Trials. 19, 1, 9 p., 383.Research output: Contribution to journal › Article › Other › peer-review
Open Access
Drug-induced Liver Injury is Frequently Associated with Severe Cutaneous Adverse Drug Reactions: Experience from Two Australian Tertiary Hospitals
Fang, W. C., Adler, N., Graudins, L. V., Goldblatt, C., Goh, M. SY., Roberts, S. K., Trubiano, J. A. & Aung, A. K., May 2018, In : Internal Medicine Journal. 48, 5, p. 549-555 7 p.Research output: Contribution to journal › Article › Research › peer-review
Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study
Ooi, G. J., Burton, P. R., Bayliss, J., Raajendiran, A., Earnest, A., Laurie, C., Kemp, W. W., McLean, C. A., Roberts, S. K., Watt, M. J. & Brown, W. A., 18 Sep 2018, (Accepted/In press) In : Obesity Surgery. 10 p.Research output: Contribution to journal › Article › Research › peer-review
Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study
Brown, A., Hézode, C., Zuckerman, E., Foster, G. R., Zekry, A., Roberts, S. K., Lahser, F., Durkan, C., Badshah, C., Zhang, B., Robertson, M., Wahl, J., Barr, E., Haber, B. & on behalf of the C-SCAPE Study, May 2018, In : Journal of Viral Hepatitis. 25, 5, p. 457-464 8 p.Research output: Contribution to journal › Article › Research › peer-review
Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy
Roberts, S. K., Lim, R., Strasser, S., Nicoll, A., Gazzola, A., Mitchell, J., Siow, W., Khoo, T., Hamarneh, Z., Weltman, M., Gow, P., Janko, N., Tse, E., Mishra, G., Cheng, E. H., Levy, M., Cheng, W., Sood, S., Skoien, R., Mitchell, J. & 8 others, 1 Feb 2018, In : Clinical Gastroenterology and Hepatology. 16, 2, p. 268-277 10 p.Research output: Contribution to journal › Article › Research › peer-review